School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
Curr Med Chem. 2011;18(26):4029-52. doi: 10.2174/092986711796957266.
Bile acids (BAs) are a family of steroidal molecules derived from cholesterol and biosynthesised in the pericentral hepatocytes of the liver. Structurally they may be regarded as consisting of two components, a rigid steroid nucleus and a short aliphatic side chain terminating in an alcohol or carboxyl group. Traditionally BAs are known for their ability to act as solubilising agents in the gut, aiding in the absorption of dietary lipids through the formation of mixed micelles. However the identification of BAs as ligands of the farnesoid X receptor (FXR) has lead to the realisation that these molecules have a wider range of biological effects. BAs regulate lipid and glucose homeostasis through activation of the FXR and the G-protein coupled receptor, TGR5. They can activate apoptotic, inflammatory and carcinogenic signalling pathways. BAs have also been shown to have anti-inflammatory effects. Interestingly, BAs are not restricted to the hepatic-intestinal system. Plasma BAs regulate BA synthesis and metabolism. BAs have recently been identified in cerebrospinal fluid. The BA, ursodeoxycholic acid has a potential role as a neuroprotectant in Huntington's disease and its taurine conjugate exhibits neuro-protective effects in vitro that may be relevant to Alzheimer's disease. This renaissance in BA biology has lead to the development of numerous medicinal chemistry programmes with different therapeutic targets, using BAs as lead structures. BA derivatives with increased efficacy and potency for FXR and TGR5 hold significant promise for the treatment of metabolic disorders. The peculiar effects of BAs on cell viability have been exploited for the design of selective cytocidal agents for treatment of various cancers. BA derivatives have also been screened with much success for anti-microbial and antifungal properties. Other targets include carbonic anhydrase for treatment of glaucoma and the glucocorticoid receptor for antiinflammatory effects. In this review interesting recent developments in the medicinal chemistry of these eclectic substances will be discussed.
胆汁酸(BAs)是一类甾体分子,来源于胆固醇,在肝脏的中央区肝细胞中生物合成。从结构上看,它们可以被认为由两个组成部分组成,一个刚性的甾体核和一个短的脂肪侧链,末端为醇或羧基。传统上,BAs 以其在肠道中作为增溶剂的能力而闻名,通过形成混合胶束有助于膳食脂质的吸收。然而,BAs 作为法尼醇 X 受体(FXR)配体的鉴定导致人们意识到这些分子具有更广泛的生物学作用。BAs 通过激活 FXR 和 G 蛋白偶联受体 TGR5 来调节脂质和葡萄糖稳态。它们可以激活凋亡、炎症和致癌信号通路。BAs 也具有抗炎作用。有趣的是,BAs 不仅限于肝肠系统。血浆 BAs 调节 BA 的合成和代谢。最近在脑脊液中发现了 BAs。BA,熊去氧胆酸在亨廷顿病中可能具有神经保护作用,其牛磺酸缀合物在体外表现出神经保护作用,这可能与阿尔茨海默病有关。BA 生物学的复兴导致了许多具有不同治疗靶点的药物化学计划的发展,使用 BAs 作为先导结构。对于 FXR 和 TGR5 具有更高疗效和效力的 BA 衍生物在治疗代谢紊乱方面具有重要的应用前景。BA 对细胞活力的特殊影响已被用于设计用于治疗各种癌症的选择性细胞毒性剂。BA 衍生物也成功地进行了抗微生物和抗真菌特性的筛选。其他靶点包括用于治疗青光眼的碳酸酐酶和用于抗炎作用的糖皮质激素受体。在这篇综述中,将讨论这些独特物质药物化学的有趣的最新进展。